Drug Trial Radar · NCT07214779
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Actual
Start
Dec 9, 2025
Primary completion
Oct 12, 2027
Study completion Oct 12, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- ENGOT Foundation; GOG Foundation
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Conditions
- Ovarian Cancer
Interventions
INCB123667Drug
Oral; tablet
Investigator's choice of chemotherapyDrug
The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by BICRTime frame: Up to 2 years
- Overall Survival (OS)Time frame: Up to 2 years
Locations
198 sites in 16 countries. Site status is shown where the registry gives one.
Alaska Womens Cancer Care Akwcc
Anchorage, Alaska
University of Arizona Cancer Center
Tucson, Arizona
City of Hope Medical Center
Duarte, California
Providence Medical Foundation
Fullerton, California
University of California, San Diego-Moores Cancer Center
La Jolla, California
Valkyrie Clinical Trials
Los Angeles, California
Uci Health Chao Family Comprehensive Cancer Center
Orange, California
Ventura County Hematology Oncology Specialists-Oxnard
Oxnard, California
University of Colorado Cancer Center
Aurora, Colorado
Mount Sinai Medical Center Comprehensive Cancer Center
Miami Beach, Florida
Brcr Global
Miramar, Florida
Sarasota Memorial Health Care System
Sarasota, Florida
Winship Cancer Institute At Emory University
Atlanta, Georgia
Georgia Cancer Center
Augusta, Georgia
The University of Chicago Medicine
Chicago, Illinois
Carle Cancer Center
Effingham, Illinois
Northshore University Health System-Evanston Hospital
Evanston, Illinois
City of Hope - Chicago Cancer Center
Zion, Illinois
St Elizabeth Healthcare
Edgewood, Kentucky
Women'S Cancer Care
Covington, Louisiana
Trials365, Llc
Shreveport, Louisiana
Maine Center For Cancer Medicine
Scarborough, Maine
Holy Cross Hospital
Silver Spring, Maryland
Greater Baltimore Medical Center
Towson, Maryland
Henry Ford Cancer - Detroit
Detroit, Michigan
Mercy Hospital St. Louis - David C. Pratt Cancer Center
St Louis, Missouri
Billings Clinic
Billings, Montana
Women'S Cancer Center of Nevada
Las Vegas, Nevada
Center of Hope
Reno, Nevada
Maimonides Medical Center
Short Hills, New Jersey
Unm Comprehensive Cancer Center
Albuquerque, New Mexico
Levine Cancer Center
Charlotte, North Carolina
Novant Presbyterian Hospital
Charlotte, North Carolina
East Carolina University
Greenville, North Carolina
Novant Health Oncology Specialists
Winston-Salem, North Carolina
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Ohio Health Research Institute
Columbus, Ohio
Miami Valley Hospital South
Dayton, Ohio
Promedica Flower Hospital
Sylvania, Ohio
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.